Intensive glycemic control, RAS blockers, SGLT2i, GLP-1RAs slow creatinine/BUN rise in adolescent DKD
Background
Diabetic kidney disease (DKD) in adolescents is an early-onset microvascular complication leading to accelerated renal decline. Elevated serum creatinine and blood urea nitrogen (BUN) are critical indicators of impaired renal function. Current management often falls short in this younger population, necessitating a clear understanding of effective pharmacological strategies. This review addresses the gap by systematically mapping and evaluating interventions specifically for adolescents (10-19 years) with DKD.
Study Design
A scoping review, adhering to PRISMA-ScR guidelines, was conducted to identify pharmacological strategies for adolescent DKD. Researchers systematically searched PubMed, Scopus, and Google Scholar for studies published between 2020 and 2025. Eligible studies included clinical trials, observational studies, clinical guidelines, and relevant reviews focusing on pharmacological interventions in adolescents aged 10-19 years with diabetic kidney disease. Study selection was based on predefined inclusion and exclusion criteria.
Results
A total of 35 studies and guideline-based references were included in the final synthesis. Intensive glycemic control, utilizing insulin for type 1 diabetes and metformin ± insulin for type 2 diabetes, consistently showed improved metabolic control and favorable renal outcomes. Renin-angiotensin system (RAS) blockers consistently reduced albuminuria and induced an acute hemodynamic reduction, while stabilizing the long-term decline in eGFR. Sodium-glucose cotransporter-2 (SGLT2) inhibitors demonstrated additional renoprotective effects in type 2 diabetes, though risks like euglycemic DKA limit their use in type 1. Finerenone, in adult studies, attenuated inflammatory and fibrotic pathways, but no adolescent data currently exist. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improved metabolic control and reduced obesity-associated renal stress. However, pediatric-specific data for GLP-1RAs remain limited.
RAS blockers consistently reduced albuminuria and stabilized the long-term decline in
eGFRin adolescent DKD.
Key Findings
- Intensive glycemic control (insulin, metformin) improves metabolic control and renal outcomes in adolescent DKD.
- Renin-angiotensin system (RAS) blockers reduce albuminuria and stabilize
eGFRdecline. - Sodium-glucose cotransporter-2 (
SGLT2) inhibitors offer renoprotection in type 2 diabetes, with caution for type 1. - Glucagon-like peptide-1 receptor agonists (
GLP-1RAs) improve metabolic control and reduce obesity-related renal stress. - Finerenone attenuates inflammatory/fibrotic pathways in adults, but adolescent data are absent.
Why It Matters
This review provides a crucial synthesis for clinicians and biohackers managing adolescent DKD, highlighting the most effective pharmacological strategies. Intensive glycemic control, RAS blockers, SGLT2 inhibitors (for T2DM), and GLP-1RAs form the cornerstone of renoprotective protocols. While SGLT2 inhibitors and GLP-1RAs show promise, the lack of extensive pediatric-specific data, particularly for finerenone and GLP-1RAs, underscores the need for further research to optimize adolescent protocols. This work emphasizes a multi-pronged approach, integrating metabolic control with targeted renal protection to slow disease progression.
diabetic kidney disease
adolescent health
pharmacological strategies
glycemic control
ras blockers
sglt2 inhibitors